PAX8 lineage-driven T cell engaging antibody for the treatment of high-grade serous ovarian cancer

PAX8 lineage-driven T cell engaging antibody for the treatment of high-grade serous ovarian cancer

Abstract High-grade serous ovarian cancers (HGSOC) represent the most common subtype of ovarian malignancies. Due to the frequency of late-stage diagnosis and high rates of recurrence following standard of care treatments, novel therapies are needed to promote durable responses. We investigated the...

Full description

Bibliographic Details
Main Authors: Emily Lee, Sarah Szvetecz, Ryan Polli, Angelo Grauel, Jayson Chen, Joyce Judge, Smita Jaiswal, Rie Maeda, Stephanie Schwartz, Bernd Voedisch, Mateusz Piksa, Chietara Japutra, Lingheswar Sadhasivam, Yiqin Wang, Ana Carrion, Sinan Isim, Jinsheng Liang, Thomas Nicholson, Hong Lei, Qing Fang, Michelle Steinkrauss, Dana Walker, Joel Wagner, Viviana Cremasco, Hui Qin Wang, Giorgio G. Galli, Brian Granda, Keith Mansfield, Quincey Simmons, Andrew Anh Nguyen, Nicole Vincent Jordan
Format: Article
Language:English
Published: Nature Publishing Group 2021-07-01
Series:Scientific Reports
Online Access:https://doi.org/10.1038/s41598-021-93992-1

Internet

https://doi.org/10.1038/s41598-021-93992-1

Similar Items